CureVac NV
(XTER:5CV)
€
2.912
-0.018 (-0.61%)
Market Cap: 667.92 Mil
Enterprise Value: 500.70 Mil
PE Ratio: 0
PB Ratio: 1.83
GF Score: 47/100 - Q4 2023 CureVac NV Earnings Call TranscriptApr 24, 2024€2.27 (-4.70%)Earnings
- Q3 2023 CureVac NV Earnings Call TranscriptNov 14, 2023€5.35 (+6.79%)Earnings
- CureVac NV at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q4 2022 CureVac NV Earnings Call TranscriptApr 25, 2023€6.95 (-5.18%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptMar 28, 2023
- CureVac NV Preliminary Phase 1 Data from Joint COVID-19 and Flu mRNA Vaccine Development Programs TranscriptJan 06, 2023
- Q3 2022 CureVac NV Earnings Call TranscriptNov 16, 2022€7.89 (+2.04%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptJun 22, 2022
- CureVac NV at JMP Securities Life Sciences Conference TranscriptJun 15, 2022
- CureVac NV at Jefferies Healthcare Conference TranscriptJun 09, 2022
- CureVac NV at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Q4 2021 CureVac NV Earnings Call TranscriptApr 28, 2022€15.2 (-1.05%)Earnings
- Q3 2021 CureVac NV Earnings Call TranscriptNov 19, 2021€36.83 (+4.54%)Earnings
- CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call TranscriptOct 12, 2021
- CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call TranscriptJul 01, 2021
- CureVac NV Updates On Clinical Trial - Corporate Call TranscriptJun 17, 2021
- Q4 2020 CureVac NV Earnings Call TranscriptApr 15, 2021€89 (+3.91%)Earnings
- CureVac N.V. - Special Call TranscriptFeb 05, 2021
CureVac NV at Bank of America Global Healthcare Conference Transcript
May 09, 2023 / 10:40PM GMT
Release Date Price:
€8
(+2.83%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Perfect. Welcome to the afternoon sessions of the BofA Healthcare Conference. So I'm Geoff Meacham, and my colleague, Charlie Yang, is on the stage with me. We're thrilled today to have CureVac and CFO, Pierre Kemula. Welcome. Thank you very much.
Pierre Kemula
CureVac N.V. - MD, CFO & Member of Management Board
Yes.
Questions & Answers
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Yes. So Pierre, maybe just give us a bit of a status update about how mRNA technology, obviously, brand new to the world, come COVID, but now we've seen an evolution of the technology. Give us kind of where you are relative to, say, Moderna or BioNTech and your biggest points of, I would say, differentiation in the technology as a starter?
Pierre Kemula
CureVac N.V. - MD, CFO & Member of Management Board
Sure. So -- and thanks for the question. So we are
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)